UK markets open in 2 hours 36 minutes

Akebia Therapeutics, Inc. (AKBA)

NasdaqCM - NasdaqCM Real-time price. Currency in USD
Add to watchlist
1.3500-0.0400 (-2.88%)
At close: 04:00PM EST
1.4200 +0.07 (+5.19%)
After hours: 08:00PM EST
Full screen
Loading interactive chart…
  • PR Newswire

    Akebia Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

    Akebia Therapeutics®, Inc. (Nasdaq: AKBA), a biopharmaceutical company with the purpose to better the lives of people impacted by kidney disease, granted five newly-hired employees options to purchase an aggregate of 856,950 shares of Akebia's common stock on January 31, 2024, including an option to purchase 454,950 shares to Nik Grund, Akebia's newly hired Chief Commercial Officer, and an option to purchase 336,000 shares to Richard Malabre, Akebia's newly hired Chief Accounting Officer. The op

  • PR Newswire

    Akebia Secures $55 Million Term Loan Financing

    Akebia Therapeutics®, Inc. (Nasdaq: AKBA), a biopharmaceutical company with the purpose to better the lives of people impacted by kidney disease, today announced it has closed a loan facility with funds and accounts managed by BlackRock. The loan provides Akebia with up to $55.0 million of borrowing capacity available in three tranches.

  • PR Newswire

    Akebia Therapeutics Announces Appointment of Nicholas Grund as Chief Commercial Officer

    Akebia Therapeutics®, Inc. (Nasdaq: AKBA), a biopharmaceutical company with the purpose to better the lives of people impacted by kidney disease, today announced the appointment of Nicholas Grund as Chief Commercial Officer. Mr. Grund is a seasoned pharmaceutical executive with significant operational, commercial and strategic leadership experience across renal and specialty markets.